Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum

[1]  C. Rogier,et al.  Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum , 2012, Malaria Journal.

[2]  B. Pradines,et al.  Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia , 2011, Malaria Journal.

[3]  R. Price,et al.  Ex Vivo Drug Susceptibility of Ferroquine against Chloroquine-Resistant Isolates of Plasmodium falciparum and P. vivax , 2011, Antimicrobial Agents and Chemotherapy.

[4]  E. Winzeler,et al.  Piperaquine Resistance Is Associated with a Copy Number Variation on Chromosome 5 in Drug-Pressured Plasmodium falciparum Parasites , 2011, Antimicrobial Agents and Chemotherapy.

[5]  S. Briolant,et al.  Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum , 2010, Malaria Journal.

[6]  Shui-sen Zhou,et al.  Geographical, meteorological and vectorial factors related to malaria re-emergence in Huang-Huai River of central China , 2010, Malaria Journal.

[7]  R. Price,et al.  In Vitro Activity of Pyronaridine against Multidrug-Resistant Plasmodium falciparum and Plasmodium vivax , 2010, Antimicrobial Agents and Chemotherapy.

[8]  P. Newton,et al.  An Open-Label, Randomised Study of Dihydroartemisinin-Piperaquine Versus Artesunate-Mefloquine for Falciparum Malaria in Asia , 2010, PloS one.

[9]  S. Briolant,et al.  Absence of Association between Piperaquine In Vitro Responses and Polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe Genes in Plasmodium falciparum , 2010, Antimicrobial Agents and Chemotherapy.

[10]  O. Gaye,et al.  Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial , 2010, The Lancet.

[11]  Sue J Lee,et al.  Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial , 2010, Malaria Journal.

[12]  P. Siba,et al.  In vitro sensitivity of Plasmodium falciparum to conventional and novel antimalarial drugs in Papua New Guinea , 2010, Tropical medicine & international health : TM & IH.

[13]  P. Rosenthal,et al.  In Vitro Sensitivities of Plasmodium falciparum to Different Antimalarial Drugs in Uganda , 2010, Antimicrobial Agents and Chemotherapy.

[14]  David A. Fidock,et al.  Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria , 2009, Nature Reviews Microbiology.

[15]  P. Rosenthal,et al.  Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  P. Rosenthal,et al.  Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. , 2009, The Journal of infectious diseases.

[17]  A. Nzila,et al.  In Vitro Activities of Piperaquine, Lumefantrine, and Dihydroartemisinin in Kenyan Plasmodium falciparum Isolates and Polymorphisms in pfcrt and pfmdr1 , 2009, Antimicrobial Agents and Chemotherapy.

[18]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[19]  B. Mordmüller,et al.  In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays , 2009, Malaria Journal.

[20]  Stephane Proux,et al.  Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment , 2009, PloS one.

[21]  David H. Gracias,et al.  Compactness Determines the Success of Cube and Octahedron Self-Assembly , 2009, PloS one.

[22]  S. Krudsood,et al.  Role of Known Molecular Markers of Resistance in the Antimalarial Potency of Piperaquine and Dihydroartemisinin In Vitro , 2009, Antimicrobial Agents and Chemotherapy.

[23]  C. Wongsrichanalai,et al.  Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia , 2009, Malaria Journal.

[24]  M. Fukuda,et al.  Evidence of artemisinin-resistant malaria in western Cambodia. , 2008, The New England journal of medicine.

[25]  B. Cissé,et al.  Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. , 2008, The Journal of infectious diseases.

[26]  Kwaku Poku Asante,et al.  An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria , 2008, PloS one.

[27]  P. Rosenthal,et al.  Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treating Uncomplicated Malaria: A Randomized Trial to Guide Policy in Uganda , 2008, PloS one.

[28]  S. Croft,et al.  Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. , 2008, Acta tropica.

[29]  K. Stȩpniewska,et al.  Population Pharmacokinetics of Piperaquine after Two Different Treatment Regimens with Dihydroartemisinin-Piperaquine in Patients with Plasmodium falciparum Malaria in Thailand , 2008, Antimicrobial Agents and Chemotherapy.

[30]  P. Rosenthal,et al.  Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  O. Gaye,et al.  Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Sénégal , 2007, Malaria Journal.

[32]  U. d’Alessandro,et al.  A Randomised Controlled Trial to Assess the Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Peru , 2007, PloS one.

[33]  P. Siba,et al.  Pharmacokinetics and Efficacy of Piperaquine and Chloroquine in Melanesian Children with Uncomplicated Malaria , 2007, Antimicrobial Agents and Chemotherapy.

[34]  R. Price,et al.  Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria , 2007, Antimicrobial Agents and Chemotherapy.

[35]  H. Myint,et al.  Efficacy and safety of dihydroartemisinin-piperaquine. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[36]  F. Nosten,et al.  In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border , 2007, Malaria Journal.

[37]  P. Rosenthal,et al.  Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial , 2007, PLoS clinical trials.

[38]  R. Price,et al.  Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  D. Warhurst,et al.  Effects of Piperaquine, Chloroquine, and Amodiaquine on Drug Uptake and of These in Combination with Dihydroartemisinin against Drug-Sensitive and -Resistant Plasmodium falciparum Strains , 2007, Antimicrobial Agents and Chemotherapy.

[40]  J. Chollet,et al.  In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. , 2007, Experimental parasitology.

[41]  F. Nosten,et al.  An open label randomized comparison of mefloquine–artesunate as separate tablets vs. a new co‐formulated combination for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand , 2006, Tropical medicine & international health : TM & IH.

[42]  J. Hamzah,et al.  In Vitro Interactions between Piperaquine, Dihydroartemisinin, and Other Conventional and Novel Antimalarial Drugs , 2006, Antimicrobial Agents and Chemotherapy.

[43]  J. Bras,et al.  Les résistances aux médicaments antipaludiques , 2006 .

[44]  C. Rogier,et al.  Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. , 2006, The American journal of tropical medicine and hygiene.

[45]  C. Rogier,et al.  In vitro activity of iron-binding compounds against Senegalese isolates of Plasmodium falciparum. , 2006, The Journal of antimicrobial chemotherapy.

[46]  C. Rogier,et al.  Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. , 2006, The American journal of tropical medicine and hygiene.

[47]  N. Day,et al.  Pitfalls in Estimating Piperaquine Elimination , 2005, Antimicrobial Agents and Chemotherapy.

[48]  T. Davis,et al.  Piperaquine , 2005, Drugs.

[49]  Nicholas J White,et al.  Antimalarial drug resistance. , 2004, The Journal of clinical investigation.

[50]  P. Ringwald,et al.  In Vitro Activities of Piperaquine and Other 4-Aminoquinolines against Clinical Isolates of Plasmodium falciparum in Cameroon , 2003, Antimicrobial Agents and Chemotherapy.

[51]  K. Bojang,et al.  Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial , 2000, The Lancet.

[52]  P. Ringwald,et al.  In Vitro Activities of Pyronaridine, Alone and in Combination with Other Antimalarial Drugs, against Plasmodium falciparum , 1999, Antimicrobial Agents and Chemotherapy.

[53]  J. Karbwang,et al.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. , 1998, British journal of clinical pharmacology.

[54]  B. Pradines,et al.  In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. , 1998, The Journal of antimicrobial chemotherapy.

[55]  N. White,et al.  Preventing antimalarial drug resistance through combinations. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[56]  S. Croft,et al.  Activity of pyronaridine and mepacrine against twelve strains of Plasmodium falciparum in vitro. , 1996, The Journal of antimicrobial chemotherapy.

[57]  D. Kyle,et al.  Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. , 1996, The American journal of tropical medicine and hygiene.

[58]  J. Le bras,et al.  In vitro activity of pyronaridine against African strains of Plasmodium falciparum. , 1992, Annals of tropical medicine and parasitology.

[59]  C. Lambros,et al.  Synchronization of Plasmodium falciparum erythrocytic stages in culture. , 1979, The Journal of parasitology.

[60]  J. Peter,et al.  Malaria Journal BioMed Central , 2008 .

[61]  B. Pradines,et al.  In vitro susceptibility of African isolates of Plasmodium falciparum from Gabon to pyronaridine. , 1999, The American journal of tropical medicine and hygiene.

[62]  W. Milhous,et al.  In vitro activity of pyronaridine against field isolates and reference clones of Plasmodium falciparum. , 1988, The American journal of tropical medicine and hygiene.